“…5) While low molecular weight heparin bridged to warfarin was once the treatment of choice, direct oral anticoagulants (DOACs) are now recommended as the first-line therapy for most patients. 7,32) DOACs including dabigatran, apixaban, rivaroxaban, and edoxaban have been shown to be non-inferior to warfarin in a series of large meta-analyses including the RE-COVER, RE-COVER II, EINSTEIN-DVT, EIN-STEIN-PE, AMPLIFY, and Hokusai-VTE trials. 33) In addition, DOACs have many potential advantages over warfarin, including rapid onset, decreased risk of bleeding, fewer food and pharmaceutical interactions, and fewer monitoring requirements.…”